LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC
XTalks
SEPTEMBER 28, 2020
The leading global life science company is set to introduce Resolution Bio’s ctDx Lung assay , a non-invasive liquid biopsy test for patients with non-small cell lung cancer (NSCLC). LabCorp (NYSE:LH) may help lead the way with its backing of Resolution Bioscience’s new diagnostic blood test for lung cancer.
Let's personalize your content